[go: up one dir, main page]

MX2017009028A - Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas. - Google Patents

Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas.

Info

Publication number
MX2017009028A
MX2017009028A MX2017009028A MX2017009028A MX2017009028A MX 2017009028 A MX2017009028 A MX 2017009028A MX 2017009028 A MX2017009028 A MX 2017009028A MX 2017009028 A MX2017009028 A MX 2017009028A MX 2017009028 A MX2017009028 A MX 2017009028A
Authority
MX
Mexico
Prior art keywords
preparation
crystal form
new crystal
method therefor
maleate
Prior art date
Application number
MX2017009028A
Other languages
English (en)
Inventor
Zhang Yanfeng
Chen Minhua
Zhang Xiaoyu
Diao Xiaojuan
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of MX2017009028A publication Critical patent/MX2017009028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a formas cristalinas novedosas de maleato de Neratinib y el método de preparación de las mismas; las formas cristalinas novedosas de maleato del compuesto de la Fórmula (I) en la presente invención tienen alta solubilidad, buena estabilidad, buena procesabilidad, fácil procedimiento post-tratamiento y otras propiedades favorables; el método de preparación es simple, de bajo costo, y tiene un valor importante para la optimización y desarrollo futuros del fármaco. (ver Fórmula).
MX2017009028A 2015-01-09 2016-01-08 Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas. MX2017009028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510012580.0A CN105367552A (zh) 2015-01-09 2015-01-09 来那替尼马来酸盐的新晶型及其制备方法
PCT/CN2016/070472 WO2016110270A1 (zh) 2015-01-09 2016-01-08 来那替尼马来酸盐的新晶型及其制备方法

Publications (1)

Publication Number Publication Date
MX2017009028A true MX2017009028A (es) 2017-09-27

Family

ID=55370239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009028A MX2017009028A (es) 2015-01-09 2016-01-08 Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas.

Country Status (8)

Country Link
US (1) US10246437B2 (es)
EP (1) EP3243819A4 (es)
JP (1) JP2018501289A (es)
CN (2) CN105367552A (es)
CA (1) CA2973853C (es)
IL (1) IL253360A0 (es)
MX (1) MX2017009028A (es)
WO (1) WO2016110270A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005418A1 (en) 2016-06-27 2018-01-04 Pliva Hrvatska D.O.O. Solid state forms of neratinib and salts thereof
CN108299391A (zh) * 2016-08-25 2018-07-20 杭州领业医药科技有限公司 来那替尼二马来酸盐的晶型及其制备方法和药物组合物
WO2018134843A1 (en) * 2017-01-23 2018-07-26 Msn Laboratories Private Limited, R&D Center Polymorphic forms of (e)-n-{4-[3-chloro-4-((pyridin-2-yl methoxy)anilino]-3-cyano-7- ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, its maleate salt and process for preparation thereof
WO2018189695A1 (en) * 2017-04-11 2018-10-18 Lupin Limited Neratinib crystalline forms and process for preparation thereof
WO2019015394A1 (zh) * 2017-07-17 2019-01-24 苏州科睿思制药有限公司 一种来那替尼单马来酸盐的晶型及其制备方法和用途
US11034656B2 (en) 2017-11-20 2021-06-15 Teligene Ltd. Maleate salts of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino) quinolin-6-yl)-4-(dimethylamino)but-2-enamide and crystalline forms thereof
CN107698563B (zh) * 2017-11-23 2020-10-30 江苏创诺制药有限公司 制备马来酸来那替尼晶型的方法
CN108299394A (zh) * 2018-02-28 2018-07-20 江苏创诺制药有限公司 来那替尼二马来酸盐晶型及其制备方法
CN110357855A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼盐酸盐晶型及其制备方法
CN109053683A (zh) * 2018-07-27 2018-12-21 苏州晶云药物科技股份有限公司 来那替尼马来酸盐晶型c的制备方法以及来那替尼马来酸盐晶型c
KR20210081367A (ko) * 2018-10-22 2021-07-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 티로신 키나아제 억제제의 말레에이트의 결정 형태 및 이의 제조 방법
CN111087384A (zh) * 2018-10-23 2020-05-01 浙江京新药业股份有限公司 一种环己烷衍生物马来酸盐的晶型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609186A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
WO2006127205A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Also Published As

Publication number Publication date
CA2973853C (en) 2019-08-27
EP3243819A1 (en) 2017-11-15
EP3243819A4 (en) 2018-06-27
CN105367552A (zh) 2016-03-02
JP2018501289A (ja) 2018-01-18
US20180265495A1 (en) 2018-09-20
CN107428727B (zh) 2021-04-27
IL253360A0 (en) 2017-09-28
US10246437B2 (en) 2019-04-02
CA2973853A1 (en) 2016-07-14
CN107428727A (zh) 2017-12-01
WO2016110270A1 (zh) 2016-07-14

Similar Documents

Publication Publication Date Title
MX2017009028A (es) Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas.
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
SG11201806348PA (en) Steroid derivative fxr agonist
MY196328A (en) New (Hetero)Aryl-Substituted-Piperidinyl Derivatives, A Process For Their Preparation And Pharmaceutical Compositions Containing Them
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
EA201500931A1 (ru) Производные пиридин-4-ила
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
JOP20170101B1 (ar) توليف مركبات إندازول
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2016006807A (es) Derivados de imidazol.
MX2018009544A (es) Metodo para preparar derivados de 4-aminoindano sustituido.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
IN2013CH04635A (es)
IN2013MU00777A (es)